Comment from BioinvestGPT

Summary: BioinvestGPT ApS, a biotechnology company, supports the pilot program by proposing a specific "tool class" for evaluation: independent, prospective, and patient-data-free mechanistic predictions of drug effect sizes. They argue that these predictions can improve Phase 1 to Phase 2 go/no-go decisions and provide a ten-element evidentiary standard for qualifying such tools.